Introduction: A substantial number of Crohn's disease (CD) patients experience side-effects
and/or non-response to medical drugs. In part, this might be attributed to the interaction of …

Background Inflammatory bowel diseases (IBD), which includes Crohn´ s disease (CD) and
ulcerative colitis (UC), are complex and heterogeneous diseases characterized by a …

Background Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An
adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology …

Abstract Background and Aims Crohn's disease [CD] is a chronic inflammatory disorder of
the gastrointestinal tract characterised by alternating periods of exacerbation and remission …

Background Gut microbiota dysbiosis is associated with the occurrence and development of
Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however …

In view of the increasing evidence that commonly prescribed, non-antibiotic drugs interact
with the gut microbiome, we re-examined the microbiota variance in inflammatory bowel …

A mutualistic relationship between the composition, function and activity of the gut
microbiota (GM) and the host exists, and the alteration of GM, sometimes referred as …

Background Emerging evidence supports that treatment of Crohn's disease (CD) can alter
the intestinal microbiota, which can play a significant role in the pathogenesis and …

Background The composition of the gut microbiota is associated with response to treatments
in inflammatory bowel disease1. We sought to identify gut microbial and metabolomic …

Growing evidence suggests that alterations in the gut microbiome impact the development of
inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis …